Clinical trials: Mecamylamine
Depressive Disorder
Nicotinic Receptor Augmentation of SSRI Antidepressants
The purpose of this study is to determine whether the nicotinic receptor antagonist mecamylamine hydrochloride (Inversine) can augment SSRI-refractory major depression symptoms, quality of life and cigarette smoking outcomes.
- Trial name
- NCT00319319
- Testing
- Mecamylamine hydrochloride (Inversine)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Yale University
Cognition in Schizophrenia
Study of the Effects of Mecamylamine and Varenicline in Schizophrenia
We are conducting this study to find out if blocking or partially stimulating the effects of nicotine in the brain can affect memory and concentration. Nicotine is the addictive drug found in tobacco products.
- Trial name
- NCT00455650
- Testing
- Mecamylamine, Varenicline
- Where
- United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital